ArticleBioData mining2026
Prognostic biomarker discovery in pancreatic cancer through hybrid ensemble feature selection and multi-omics data.
Article in BioData mining, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate prediction of patient survival using high-dimensional multi-omics data requires effective feature selection methods that balance predictive performance, sparsity, and stability to enable reproducible and transparent prognostic biomarker discovery. Existing approaches often rely on ad hoc thresholds, limiting their reproducibility and clinical utility.
methodsWe developed a hybrid ensemble feature selection (hEFS) framework that integrates data subsampling with multiple prognostic models, combining embedded and wrapper-based strategies for survival prediction. Features are ranked using a voting-theory-inspired aggregation approach across models and subsamples, while the optimal feature subset is determined via Pareto front optimization, eliminating the need for user-defined thresholds. We benchmarked hEFS against conventional CoxLasso using 100 Monte Carlo cross-validation iterations on multi-omics datasets from three pancreatic ductal adenocarcinoma (PDAC) cohorts, assessing sparsity, stability, redundancy, discrimination, and computational cost.
resultsAcross all cohorts, hEFS selected substantially fewer and more stable features than CoxLasso (~10 vs. ~60 per modality), with lower variance, while still maintaining comparable discrimination performance with clinical baselines (C-index ~0.54–0.60). Feature redundancy was low, and ensemble subsampling further improved stability. Prognostic performance depended mainly on modality choice, rather than integration model, with gene expression plus clinical variables achieving the highest discrimination power (C-index ~0.64).
conclusionshEFS provides a fully automated, interpretable, and reproducible framework for multi-omics biomarker discovery in high-dimensional survival analysis. By producing sparse, yet stable biomarker panels without loss of predictive power, hEFS represents a practical tool for integrative multi-omics modeling and it is openly available in the mlr3fselect R package.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.